StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
BTX opened at $6.33 on Friday. The company has a market capitalization of $372.37 million, a PE ratio of -2.79 and a beta of 4.61. The stock’s fifty day moving average is $3.87 and its 200-day moving average is $1.84. Brooklyn ImmunoTherapeutics has a one year low of $6.22 and a one year high of $8.31.
Brooklyn ImmunoTherapeutics Dividend Announcement
The firm also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, March 14th will be paid a $0.0862 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 16.33%. Brooklyn ImmunoTherapeutics’s dividend payout ratio is currently -38.33%.
About Brooklyn ImmunoTherapeutics
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What Are Earnings Reports?
- MarketBeat Week in Review – 03/24 – 03/28
- What is Short Interest? How to Use It
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
